Speaking Engagements
Healthcare Securities Class Actions, SEC Enforcement & Emerging Capital Markets Risks
September 2, 2026
Douglas G. Gray, a partner in Troutman Pepper Locke’s Health Care + Life Sciences Department, was quoted in the July 27, 2026, Life Sciences IP Review article, “Buying the Brains: Why Is Big Pharma Shopping for Innovation?“
- Douglas Gray, partner at Troutman, believes that the patent cliff has triggered “a serious hunt for new compounds” to replace declining revenues.
- In the US, Gray says that buyers want assets that are sufficiently “de-risked” to provide a clear path to FDA approval, while still offering a significant revenue opportunity to “offset the risk to the buyer and its shareholders”
- He adds that the level of risk buyers are prepared to accept depends on the type of product.
- “Novel drugs, whether delivery or compound, may need to be more de-risked before acquisition than a biosimilar because the path to FDA approval may require more effort and data,” explains Gray, while manufacturing costs, transport and the method of administration can all influence a deal.
Insight Industries + Practices
This just in
Firm Events
Cocktails and Networking During MEDevice Boston
August 26, 2026 | 6:00 PM – 8:00 PM ET
Lifted Restaurant
450 Summer St, Boston, MA 02210
Speaking Engagements
The 2026 Multifamily Maturity Cliff: Reading the $162 Billion Refinancing Wave and the Engagements It Will Generate
August 26, 2026 | 1:00 PM – 3:10 PM ET
Webinar
Speaking Engagements
ILTACON 2026 Conference
August 23 – 27, 2026
Gaylord Opryland Resort & Convention Center
2800 Opryland Dr, Nashville, TN 37214